Summit’s bispecific stumbles in global study, but was it the right test case?

The highly anticipated readout for ivonescimab wasn’t what investors hoped for, but the results don’t necessarily undermine confidence in China-only studies or the bispecific’s broader lung cancer potential.

On Friday, as the American Society of Clinical Oncology (ASCO) meeting kicked off in Chicago, Summit Therapeutics Inc. (NASDAQ:SMMT) reported that the PD-1 x VEGF bispecific, which it licensed from Akeso Inc. (HKEX:9926), met the primary progression-free survival endpoint (PFS), but not overall survival (OS), in the global Phase III HARMONi study...